Septerna, Inc. Common Stock (SEPN) - Net Assets
Based on the latest financial reports, Septerna, Inc. Common Stock (SEPN) has net assets worth $378.46 Million USD as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($569.69 Million) and total liabilities ($191.23 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore Septerna, Inc. Common Stock asset portfolio for the complete picture of this company's asset base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $378.46 Million |
| % of Total Assets | 66.43% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
Septerna, Inc. Common Stock - Net Assets Trend (2022–2025)
This chart illustrates how Septerna, Inc. Common Stock's net assets have evolved over time, based on quarterly financial data. Check tangible equity quality of Septerna, Inc. Common Stock to evaluate the tangible quality of the company's equity base.
Annual Net Assets for Septerna, Inc. Common Stock (2022–2025)
The table below shows the annual net assets of Septerna, Inc. Common Stock from 2022 to 2025. For live valuation and market cap data, see Septerna, Inc. Common Stock (SEPN) market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $381.93 Million | -9.08% |
| 2024-12-31 | $420.05 Million | +1194.61% |
| 2023-12-31 | $-38.37 Million | +13.18% |
| 2022-12-31 | $-44.20 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Septerna, Inc. Common Stock's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 11649700000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $45.00K | 0.01% |
| Other Comprehensive Income | $617.00K | 0.16% |
| Other Components | $548.52 Million | 143.62% |
| Total Equity | $381.93 Million | 100.00% |
Septerna, Inc. Common Stock Competitors by Market Cap
The table below lists competitors of Septerna, Inc. Common Stock ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Yangling Metron New Material Co Ltd
SHE:300861
|
$1.55 Billion |
|
Molymet
SN:MOLYMET
|
$1.55 Billion |
|
China Railway Construction Corporation Limited
F:4FF
|
$1.55 Billion |
|
Galapagos N.V.
AS:GLPG
|
$1.55 Billion |
|
Triangle Tyre Co Ltd
SHG:601163
|
$1.55 Billion |
|
Zhejiang Zhongjian Technology Co Ltd
SHE:002779
|
$1.55 Billion |
|
Kernel Holding SA
WAR:KER
|
$1.55 Billion |
|
Hope Bancorp Inc
NASDAQ:HOPE
|
$1.55 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Septerna, Inc. Common Stock's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 420,047,000 to 381,926,000, a change of -38,121,000 (-9.1%).
- Net loss of 48,879,000 reduced equity.
- Share repurchases of 1,000 reduced equity.
- Other comprehensive income increased equity by 561,000.
- Other factors increased equity by 10,198,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-48.88 Million | -12.8% |
| Share Repurchases | $1.00K | -0.0% |
| Other Comprehensive Income | $561.00K | +0.15% |
| Other Changes | $10.20 Million | +2.67% |
| Total Change | $- | -9.08% |
Book Value vs Market Value Analysis
This analysis compares Septerna, Inc. Common Stock's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 3.99x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2022-12-31 | $-2.27 | $34.45 | x |
| 2023-12-31 | $-1.97 | $34.45 | x |
| 2024-12-31 | $11.29 | $34.45 | x |
| 2025-12-31 | $8.63 | $34.45 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Septerna, Inc. Common Stock utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -12.80%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -106.37%
- • Asset Turnover: 0.08x
- • Equity Multiplier: 1.56x
- Recent ROE (-12.80%) is below the historical average (-7.47%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2022 | 0.00% | 0.00% | 0.00x | 0.00x | $-23.26 Million |
| 2023 | 0.00% | 2768.21% | 0.00x | 0.00x | $8.02 Million |
| 2024 | -17.09% | -6678.88% | 0.00x | 1.09x | $-113.80 Million |
| 2025 | -12.80% | -106.37% | 0.08x | 1.56x | $-87.07 Million |
Industry Comparison
This section compares Septerna, Inc. Common Stock's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $128,838,508
- Average return on equity (ROE) among peers: -63.38%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Septerna, Inc. Common Stock (SEPN) | $378.46 Million | 0.00% | 0.51x | $1.55 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-34.80 Million | 0.00% | 0.00x | $143.70 Million |
| Abcellera Biologics Inc (ABCL) | $1.15 Billion | -12.70% | 0.29x | $1.61 Billion |
| Abeona Therapeutics Inc (ABEO) | $9.08 Million | -66.39% | 1.81x | $335.61 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $-11.42 Million | 0.00% | 0.00x | $155.29 Million |
| Abpro Holdings, Inc. (ABP) | $3.07 Million | -479.81% | 1.57x | $2.00 Million |
| Absci Corp (ABSI) | $179.13 Million | -57.56% | 0.19x | $1.01 Billion |
| Arbutus Biopharma Corp (ABUS) | $-18.49 Million | 0.00% | 0.00x | $831.63 Million |
| ABVC Biopharma Inc (ABVC) | $-2.01 Million | 0.00% | 0.00x | $26.26 Million |
| Abivax SA American Depositary Shares (ABVX) | $34.02 Million | -17.32% | 0.13x | $10.89 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $-22.51 Million | 0.00% | 0.00x | $3.66 Billion |
About Septerna, Inc. Common Stock
Septerna, Inc., a clinical-stage biotechnology company, discovers and develops G protein-coupled receptor (GPCR) oral small molecule products for the treatment of endocrinology, immunology and inflammation, and metabolic diseases. It develops PTH1R Program, oral small molecule Parathyroid Hormone 1 Receptor agonists for the treatment of hypoparathyroidism; SEP-631, an oral small molecule MRGPRX2 … Read more